Intracranial hypertension is a major cause of morbidity and mortality in patients with brain injury. If not appropriately treated, it can precipitate brain ischemia, brain herniation and death. Hyperosmolar therapy remains the main armamentarium for management of raised intracranial pressure, especially in patients with diffuse lesions and where surgical options are not applicable. Substantial amount of studies have tried to explore the superiority of hypertonic saline or mannitol over the other. Due to significant heterogeneity in the pathophysiology of patients, variation in treatment threshold, method of drug administration and drug concentration, substantial evidence is lacking to support one agent over other. Hypertonic saline may be more effective than mannitol for lowering raised intracranial pressure. Well designed novel trials need to try to find the answer. Clinical, pathophysiological and biochemical data should be incorporated at bedside while individualizing selection of hyperosmolar therapy, with the aim to improve outcome and minimize harm.
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How to cite this article: Shrestha GS. Individualizing hyperosmolar therapy for management of intracranial hypertension. Journal of Society of Anesthesiologists of Nepal (JSAN) 2017;4(2):54-56. yperosmolar agents remain the mainstay of therapy for management of intracranial hypertension. 1 Use of mannitol or hypertonic saline is recommended in the early steps or early tiers while managing raise intracranial pressure (ICP). Recent practice guidelines fail to provide specific recommendations in favor of one agent over another. It is due to low level of precision and insufficient quality of evidence from the existing studies and trials. 5 Meta-analysis of randomized trials involving six studies and 171 patients comparing mannitol and HS for management of raised ICP in patients with traumatic brain injury (TBI) suggest a trend favoring the use of HTS over mannitol. However, multiple methodological limitations exist in the meta-analysis like different formulations and dose of HTS used in studies, heterogeneous patient population and varying threshold of ICP used for treatment. 6 At equimolar dose, HTS may be more effective than mannitol in patients with TBI and may confer longer duration of ICP reduction. At 30 minutes after administration, there was no difference in ICP reduction between HTS and mannitol, but the ICP reduction was more significant at 60 and 120 minutes. 7 However, uncertainty persists about the preferred agent in patients with raised ICP due to different pathological conditions. The optimal means (bolus or continuous infusion), dose and concentration of administration are yet to be determined. The effect of hyperosmolar agents on neurological and long term outcomes need to be explored. 5, 7 Patients with brain injury and intracranial hypertension are heterogeneous. 8, 9 Current understanding from the studies and guidelines are unable to recommend one agent over the other, except for the trend in favor of HTS over mannitol. [5] [6] [7] Precision oriented future randomized controlled trial can be challenged by the significant heterogeneity of patient population, resulting in smaller homogenous groups and a longer time frame required for recruitment of patients. Registry based randomized controlled trial involving large collaborative multicentric data registry can retain the benefit of randomization and at the same time facilitate rapid recruitment of samples with cost effectiveness. As the patient outcome is dependent on multiple interventions occurring simultaneously, effectiveness of individual treatment can be tested using platform trials. Though it sound intriguing and promising, the path for finding precision in managing intracranial hypertension is challenging, more so in places with resource limitations. 10 [4] [5] [6] [7] It would be prudent to incorporate the available clinical and biochemical data to individualize hyperosmolar therapy in patients with intracranial hypertension, in an attempt to improve patient outcome and to avoid harm.
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